Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly making false and misleading statements regarding the safety of its Enfamil formula, particularly concerning the risk of necrotizing enterocolitis in preterm infants [4]. Group 1: Lawsuit Details - The lawsuit is based on violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased Reckitt's securities between January 13, 2021, and July 28, 2024, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Reckitt failed to disclose the increased risk of necrotizing enterocolitis (NEC) associated with its Enfamil formula for preterm infants [4]. - The company is accused of misleading investors about its exposure to legal claims related to NEC, resulting in materially false public statements throughout the class period [4]. - As a result of the revelations, investors reportedly suffered damages when the truth about Reckitt's practices became known [4].